DHR250117C105000
- 169.40
- 0.000.00%
Danaher Newsroom
J.P. Morgan Maintains Danaher(DHR.US) With Buy Rating, Cuts Target Price to $300
Danaher (DHR) Receives a Buy From J.P. Morgan
JPMorgan Adjusts Price Target on Danaher to $300 From $310, Maintains Overweight Rating
Apple, AT&T, Tesla, GM, Microsoft, and More Stocks to Watch This Week
Earnings Week Ahead: TSLA, META, AAPL, MSFT, INTC, MA, XOM, LUV and More
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Earnings Preview: Danaher to Report Financial Results Pre-market on January 29
$Danaher(DHR.US)$ is scheduled to release its financial results pre-market on January 29 ET. Earnings PreviewAnalysts estimate $Danaher(DHR.US)$ to post revenue of USD6.46B for 2024Q4, up 0.9% YOY;
Is Danaher Corporation (DHR) the Best Diversified Dividend Stock to Buy Now?
This Healthcare Stock Might Just Be RFK Jr. Proof -- Barrons.com
Danaher Is Maintained at Outperform by Raymond James
Danaher Analyst Ratings
Raymond James Maintains Danaher(DHR.US) With Buy Rating, Cuts Target Price to $275
Express News | Danaher Corp : Raymond James Cuts Target Price to $275 From $300
Aldevron Unveils Next-Generation Alchemy Cell-Free DNA Technology for Research Grade Applications
Least Shorted S&P 500 Stocks in December
Today's Analyst Rating | TD Cowen Cuts Its Price Target Cut on Eli Lilly and Co to $900, JPMorgan Price Target Raised to $295 by Goldman Sachs
Jan 16, Wall Street analysts have updated their stock ratings today including $Eli Lilly and Co(LLY.US)$ and $JPMorgan(JPM.US)$.
Goldman Sachs Maintains Danaher(DHR.US) With Hold Rating, Raises Target Price to $250
Goldman Sachs Adjusts Danaher Price Target to $250 From $255
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research